TABLE 1.

FATP4, CD36, and ACSL1 expression with the clinicopathologic parameters of non-muscle-invasive urothelial carcinoma.

Characteristics		FATP4		p	CD36		p	ACSL1		p
		High (n = 123) No. (%)	Low (n = 163) No. (%)		High (n = 43) No. (%)	Low (n = 243) No. (%)		High (n = 35) No. (%)	Low (n = 251) No. (%)
Age	Low (<68 years)	59 (48.0)	80 (49.1)	0.852	21 (48.8)	118 (48.6)	0.973	18 (51.4)	121 (48.2)	0.721
	High (≥68 years)	64 (52.0)	83 (50.9)		22 (51.2)	125 (51.4)		17 (48.6)	130 (51.8)
Sex	Male	106 (86.2)	148 (90.8)	0.220	39 (90.7)	215 (88.5)	0.798	31 (88.6)	223 (88.8)	1.000
	Female	17 (13.8)	15 (9.2)		4 (9.3)	28 (11.5)		4 (11.4)	28 (11.2)
Grade	Low	50 (40.7)	94 (57.7)	0.004	10 (23.3)	134 (55.1)	<0.001	5 (14.3)	139 (55.4)	<0.001
	High	73 (59.3)	69 (42.3)		33 (76.7)	109 (44.9)		30 (85.7)	112 (44.6)
T stage	Low (Ta)	55 (44.7)	93 (57.1)	0.039	13 (30.2)	135 (55.6)	0.002	11 (31.4)	137 (54.6)	0.010
	High (T1)	68 (55.3)	70 (42.9)		30 (69.8)	108 (44.4)		24 (68.6)	114 (45.4)
Growth type	Papillary	91 (74.0)	130 (79.7)	0.249	26 (60.5)	195 (80.2)	0.004	20 (57.1)	201 (80.1)	0.002
	Non-papillary	32 (26.0)	33 (20.2)		17 (39.5)	48 (19.8)		15 (42.9)	50 (19.9)
Lymphatic invasion	Absent	121 (98.4)	158 (96.9)	0.703	42 (97.7)	237 (97.5)	1.000	34 (97.1)	245 (97.6)	1.000
	Present	2 (1.6)	5 (3.1)		1 (2.3)	6 (2.5)		1 (2.9)	6 (2.4)
Metastasis	Absent	115 (93.5)	155 (95.1)	0.609	38 (88.4)	232 (95.5)	0.074	30 (85.7)	240 (95.6)	0.033
	Present	8 (6.5)	8 (4.9)		5 (11.6)	11 (4.5)		5 (14.3)	11 (4.4)
Recurrence	Absent	68 (55.3)	87 (53.4)	0.748	22 (51.2)	133 (54.7)	0.665	19 (54.3)	136 (54.2)	0.991
	Present	55 (44.7)	76 (46.6)		21 (48.8)	110 (45.3)		16 (45.7)	115 (45.8)